We advised the book-running manager on the offering

Davis Polk advised the sole book-running manager in connection with a public offering by Immix Biopharma, Inc. of 11,363,637 shares of common stock at $11.00 per share for total gross proceeds of approximately $125 million. The common stock is listed on the Nasdaq Capital Market under the symbol “IMMX.”

Immix Biopharma is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor therapy (CAR-T) in light chain (AL) amyloidosis and other serious diseases.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Alexander Curtis and Alexis Aguila Johnson. Counsel Dustin Plotnick and associates Isaiah B. Kramer and Sophia Kwende provided tax advice. Partner David R. Bauer and associate Anne Kim provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post